KRYS
Krystal Biotech Inc.
Company Overview
| Mkt Cap | $5.74B | Price | $348.06 |
| Volume | 811.43K | Change | +1.87% |
| P/E Ratio | 28.0 | Open | $350.00 |
| Revenue | $389.1M | Prev Close | $341.66 |
| Net Income | $204.8M | 52W Range | $127.99 - $331.49 |
| Div Yield | N/A | Target | $331.00 |
| Overall | 75 | Value | 65 |
| Quality | 60 | Technical | 100 |
No chart data available
About Krystal Biotech Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Latest News
Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)
Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KRYS | $348.06 | +1.9% | 811.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |